Becoming the Leader of Drug Regeneration to Bring First-in-class Therapies for Untreated Serious Diseases

About Us

4P-Pharma is a clinical stage biotech company founded in Lille in 2014. We focus on untreated serious diseases with high unmet medical needs, aiming to rapidly deliver effective, regenerated, first-in-class therapies.

The company has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver optimized risk adjusted returns. We leverage assets with a short time to market, strong IP position, and regulatory opportunities (emergency use or conditional marketing authorizations) in blue-ocean markets.

4P-Pharma’s Major Achievements

2014
FOUNDATION
of 4P-Pharma
≥ 350
≥ 350 screened candidates from different source of innovation
≥ 25 candidates evaluated in 4P-Pharma Development’s engine
3 candidates selected for first-in-human
≥ 20
≥ 20 PARTNERSHIPS
with big pharmaceutical companies, innovation sources (biotech companies, SATTs, universities, hospitals, etc.) in France and worldwide
2
2 DISTINCTIONS
- BPI France Excellence
- Seal of Excellence from the European Commission
2
2 SPIN-OFF COMPANIES
2 clinical-stage single product vehicle companies:
- 4Moving Biotech
- 4Living Biotech
2014
FOUNDATION
of 4P-Pharma
≥ 350
≥ 350 screened candidates from different source of innovation
≥ 25 candidates evaluated in 4P-Pharma Development’s engine
3 candidates selected for first-in-human
≥ 20
≥ 20 PARTNERSHIPS
with big pharmaceutical companies, innovation sources (biotech companies, SATTs, universities, hospitals, etc.) in France and worldwide
2
2 DISTINCTIONS
- BPI France Excellence
- Seal of Excellence from the European Commission
2
2 SPIN-OFF COMPANIES
2 clinical-stage single product vehicle companies:
- 4Moving Biotech
- 4Living Biotech
FOUNDATION
of 4P-Pharma

Our Approach : circular pharmaceutical development

4P-Pharma aims to bring to patients’ curative solutions faster by moving away from current linear pharmaceutical development towards circular one :

  • Linking innovative cellular target to disease’s biology
  • Regenerate active existing drugs
  • Supporting our clinical trials by in silico and data based clinical trials
  • Leveraging on regulatory fast track to target large unmet medical needs

Our Business Model: Translating science to medicines for patients

We aim to evaluate innovative programs with strong scientific rationale, sourced from the top academic research labs and AI tech companies.

Our R&D capabilities within Pasteur Institute at Lille allow us to assess breakthrough innovations by regenerating active drugs as proprietary first-in-class therapies in the new indication.

Once reaching regulatory milestones, we launch single product vehicles (SPVs), in charge of advancing the assets through accelerated clinical development to market approvals and distribution agreements by geographic and therapeutic area.

Sourcing our therapeutic candidates

  • Discovery stage candidates with established MoA
  • Open innovation strategy in cutting-edge tech network (Research centers, Hospitals, Universities, Biotechs and AI tech companies)

Reaching clinical proof of concept

  • Asset Centric Vehicle incorporation supported by solid preclinical package and proprietary IP portfolio
  • Accelerated clinical development through regulatory opportunities (emergency use or conditional market authorization)
  • Distribution agreements by geographic and therapeutic area

Our Daughter Companies

4Living Biotech is dedicated to the clinical development of 4P021, a drug candidate for a curative treatment of acute respiratory distress syndrom (ARDS) and pulmonary complications.

We obtained clinical trial authorizations for phase 2b in severe COVID-19 and we are currently conducting in silico phase II clinical trial for ARDS to enlarge patient population (sepsis, pneumonia, etc).

4Moving Biotech is dedicated to the clinical development of 4P004, a disease modifying drug candidate for osteoarthritis showing anti-inflammatory, anti-catabolic and anabolic properties.

4Moving Biotech completed the recruitment of its Phase I clinical trial in patients with knee osteoarthritis

Pipeline

Respiratory infection

4P021

4Living Biotech

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase II

Summary:
4P021 is a CXCR4 antagonist for a curative treatment of acute respiratory distress syndrom (ARDS) and pulmonary complications.

4P021 was developed in collaboration with Prof. Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille.

Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.

Epidemiology:
Influenza virus infections are associated to more than 5 million of hospitalization worldwide per year (Lafond et al. 2021).
In France, in 2021, COVID-19 was associated with a minimum of 859 and up to 6,001 (mean 2,669) daily intensive care bed occupancies. In the United States, it was associated with a minimum of 3,525 and a maximum of 28,891 (mean 13,978) daily critical care bed occupancies (Our World in Data website).

Osteoarthritis

4P004

4Moving Biotech

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase I

Summary:
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.

4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech.

Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.

Milestone:
Phase I trial on OA patients

Market:
≥ 300 Millions of people have OA in the world (Kloppenburg et al., 2020)

Estimated sales per year : 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)

Our Partners

News

4P-Pharma at BIO Europe Spring 2024

We look forward to attending BIOEuropeSpring, which will take place on March 18-20, 2024, in Barcelona. Our Business Development team, Roselina Lam and Daniel Sanchez Lopez, will represent us at this biopharma industry event. If you’re interested in learning more about our activities and pipeline or would like to schedule a meeting, please get in&hellip

Read More

HAPPY NEW YEAR 2024

The 4P-Pharma team sends you warm wishes for a fantastic year of 2024 filled with success, achievement, and unforgettable moments. We are thrilled to celebrate the first decade of our company foundation. Over the past ten years, we have faced challenges, deepened our understanding, and solved complex scientific questions. Each year has brought us joy,&hellip

Read More

4Moving Biotech forms its Scientific Advisory Board of World-Renowned Knee Osteoarthritis Experts

4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate’s phase 2b clinical trial.   “With their expertise in clinical study design and regulatory affairs, this high-level scientific advisory board will greatly contribute to the future success of 4P004, reinforcing our pioneering position in developing&hellip

Read More
Contact us

Send us an e-mail

Lille
Campus de l’Institut Pasteur de Lille
1 Rue du Professeur Calmette
59000 Lille, France
Locate on Maps
Paris
74 rue du Faubourg Saint-Antoine
75012 Paris, France
Locate on Maps
Paris
BEYOND - Relations Presse
43 rue Condorcet 75009 PARIS
Najette Chaib
nchaib@beyondcom.fr
+ 33 6 18 38 11 14
Locate on Maps